Immunologic events during the incubation period of hepatitis C virus infection: The role of antibodies to E2 glycoprotein

Transfusion

Volumn 37, Issue 8, 1997, Pages 858-862

  Psichogiou, M ^a   Katsoulidou, A ^a   Vaindirli, E ^a   Francis, B ^b   Lee, S R ^c   Hatzakis, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

^c Hepatitis Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN E2; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INCUBATION TIME; SCREENING; SEROCONVERSION; VIRUS ENVELOPE;

EID: 0030765872     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1997.37897424411.x     Document Type: Article

References (16)

1. Vrielink H, Zaaijer HL, Reesink HW, et al. Comparison of two anti-hepatitis C virus enzyme-linked immunosorbent assays. Transfusion 1995;35:601-4.
2. Lee SR, Wood CL, Lane MJ, et al. Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay. Transfusion 1995;35:845-9.
3. Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995;68:15-8.
4. Mita E, Hayashi N, Ueda K, et al. Expression of MBP-HCV NS1/E2 fusion protein in E. coli and detection of anti-NS1/E2 antibody in type C chronic liver disease. Biochem Biophys Res Commun 1992;183:925-30.
5. Hsu HH, Donets M, Greenberg HB, Feinstone SM. Characterization of hepatitis C virus structural proteins with a recombinant baculovirus expression system. Hepatology 1993;17:763-71.
6. Spaete RR, Alexander D, Rugroden ME, et al. Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. Virology 1992;188:819-30.
7. Chien DY, Choo QL, Ralston R, et al. Persistence of HCV despite antibodies to both putative envelope glycoproteins (letter). Lancet 1993;342:933.
8. Simmonds P, Smith DB, McOmish F, et al. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 1994;75:1053-61.
9. Vernelen K, Claeys H, Verhaert H, et al. Significance of NS3 and NS5 antigens in screening for HCV antibody (letter). Lancet 1994;343:853.
10. Goffin E, Pirson Y, Cornu C, et al. Significance of NS3 and NS5 antigens in screening for HCV antibody (letter). Lancet 1994;343:854.
11. Couroucé AM, Le Marrec N, Girault A, et al. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second-and third-generation anti-HCV assays. Transfusion 1994;34:790-5.
12. Pawlotsky JM, Maisonneuve P, Duval J, et al. Significance of NS5-"indeterminate" third-generation anti-hepatitis C virus serologic assays (letter). Transfusion 1995;35:453-4.
13. Zaaijer HL, Vallari DS, Cunningham M, et al. E2 and NS5: new antigens for detection of hepatitis C virus antibodies. J Med Virol 1994;44:395-7.
14. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
15. Lesniewski RR, Boardway KM, Casey JM, et al. Hypervariable 5'-terminus of hepatitis C virus E2/NS1 encodes antigenically distinct variants. J Med Virol 1993;40:150-6.
16. Lesniewski R, Okasinski G, Carrick R, et al. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J Med Virol 1995;45:415-22.